Developing animal models to improve HIV vaccine design
Official title: Scientific Core: Animal Models
Funded at Scripps Research Institute, the · NIH-11076798 · Data updated 2026-11-12
This study is working on creating special mice that have human-like immune systems to help scientists find better vaccines for HIV, making it easier to understand how our bodies fight the virus and test new vaccine ideas.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | June 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $240,450 |
| NIH project number | 5P01AI177683-03 |
| Project ID | NIH-11076798 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of HIV infection or those interested in participating in HIV vaccine trials.
✕Less likely to help
Patients who are already living with HIV and are not eligible for vaccine trials may not benefit directly from this research.
What this research studies
This research focuses on creating advanced animal models to aid in the development of effective vaccines against HIV. By utilizing humanized mice with human B cell receptors, researchers can better understand how the immune system responds to HIV and test new vaccine candidates. The project aims to generate new mouse lines that reflect the human immune response, which will be used in various immunization experiments. This innovative approach is expected to enhance the design and evaluation of HIV vaccines.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV vaccines, ultimately reducing the incidence of HIV infections and improving patient outcomes.
How similar studies have gone: Previous research using humanized mouse models has shown promise in advancing vaccine development, indicating that this approach could yield significant results.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Batista, Facundo Damian — Scripps Research Institute, the
- Study coordinator: Batista, Facundo Damian
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.